Current status of nanoscale drug delivery and the future of nano-vaccine development for leishmaniasis – A review

Autor: Prasanna, Pragya, Kumar, Prakash, Kumar, Saurabh, Rajana, Vinod Kumar, Kant, Vishnu, Prasad, Surendra Rajit, Mohan, Utpal, Ravichandiran, V., Mandal, Debabrata

Publikováno v: In Biomedicine & Pharmacotherapy September 2021 141

Yuflyma, A High Concentration and Citrate-free Adalimumab Biosimilar, Received FDA Approval for Treating Different Forms of Inflammato ry Diseases.

Autor: Rajana VK; Department of Biotechnology, National Institute of Pharmaceutical Education and Research, Hajipur, 844102, India., Penumaka SM; Department of Biotechnology, National Institute of Pharmaceutical Education and Research, Hajipur, 844102, India., Saritha C; Department of Biotechnology, National Institute of Pharmaceutical Education and Research, Hajipur, 844102, India., Ravichandiran V; Department of Natural Products, National Institute of Pharmaceutical Education and Research, Kolkata, 700054, India., Mandal D; Department of Biotechnology, National Institute of Pharmaceutical Education and Research, Hajipur, 844102, India.

Publikováno v: Anti-inflammatory & anti-allergy agents in medicinal chemistry [Antiinflamm Antiallergy Agents Med Chem] 2023; Vol. 22 (4), pp. 273-275.